{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:12:21Z","timestamp":1793506341932,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:00:00Z","timestamp":1687910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.leukres.2023.107349","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T12:47:06Z","timestamp":1687956426000},"page":"107349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The presence of additional cytogenetic aberrations in chronic myeloid leukemia cells at the time of diagnosis or their appearance on tyrosine kinase inhibitor therapy predicts the imatinib treatment failure"],"prefix":"10.1016","volume":"132","author":[{"given":"B\u0142a\u017cej","family":"Ratajczak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Przyby\u0142owicz-Chalecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Czerwi\u0144ska-Rybak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Kandu\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Ustaszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Jarmu\u017c-Szymczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.leukres.2023.107349_bib1","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1080\/14737159.2017.1383156","article-title":"Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update","volume":"17","author":"Molica","year":"2017","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"1","key":"10.1016\/j.leukres.2023.107349_bib2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12032-012-0443-1","article-title":"Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia","volume":"30","author":"Bozkurt","year":"2013","journal-title":"Med Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2023.107349_bib3","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/leu.2016.231","article-title":"Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"31","author":"Chen","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2023.107349_bib4","unstructured":"Mitelman, F., Johansson, B., Mertens, F. Mitelman database of chromosome aberrations and gene fusions in cancer. https:\/\/mitelmandatabase.isb\u2010cgc.org (2022). Accessed 13 Dec 2021."},{"issue":"18","key":"10.1016\/j.leukres.2023.107349_bib5","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1002\/cncr.30767","article-title":"Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: the experience of the international registry for chronic myeloid leukemia in children and adolescents","volume":"123","author":"Millot","year":"2017","journal-title":"Cancer"},{"issue":"22","key":"10.1016\/j.leukres.2023.107349_bib6","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","article-title":"Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.leukres.2023.107349_bib7","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2023.107349_bib8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/15384047.2017.1294289","article-title":"Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression","volume":"18","author":"Akram","year":"2017","journal-title":"Cancer Biol. Ther."},{"issue":"11","key":"10.1016\/j.leukres.2023.107349_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.96","article-title":"Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia","volume":"6","author":"Wang","year":"2016","journal-title":"Blood Cancer J."},{"issue":"20","key":"10.1016\/j.leukres.2023.107349_bib10","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2023.107349_bib11","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2023.107349_bib12","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.leukres.2023.107349_bib13","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1182\/bloodadvances.2017011858","article-title":"Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy","volume":"1","author":"Gong","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2023.107349_bib14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13045-015-0128-2","article-title":"Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis","volume":"8","author":"Wang","year":"2015","journal-title":"J. Hematol. Oncol."},{"issue":"14","key":"10.1016\/j.leukres.2023.107349_bib15","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2015-05-646489","article-title":"Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2023.107349_bib16","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00277-015-2494-9","article-title":"Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML","volume":"94","author":"Fabarius","year":"2015","journal-title":"Ann. Hematol."},{"issue":"12","key":"10.1016\/j.leukres.2023.107349_bib17","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2023.107349_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood.V100.1.29","article-title":"Southwest oncology group. impact of trisomy 8 (+8) on clinical presentation treatment response and survival in acute myeloid leukemia: a southwest oncology group study","volume":"100","author":"Wolman","year":"2002","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2023.107349_bib19","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1038\/leu.2014.114","article-title":"Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8","volume":"28","author":"Becker","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.leukres.2023.107349_bib20","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3324\/haematol.2009.019109","article-title":"Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy","volume":"95","author":"Lippert","year":"2010","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.leukres.2023.107349_bib21","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1182\/blood-2017-07-792143","article-title":"Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment","volume":"130","author":"Issa","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2023.107349_bib22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cell.2014.02.019","article-title":"A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia","volume":"157","author":"Gr\u00f6schel","year":"2014","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.leukres.2023.107349_bib23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccr.2014.02.008","article-title":"A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression","volume":"25","author":"Yamazaki","year":"2014","journal-title":"Cancer Cell."},{"issue":"3","key":"10.1016\/j.leukres.2023.107349_bib24","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/sj.mt.6300372","article-title":"The MDS1-EVI1 gene complex as a retrovirus integration site: impact on behavior of hematopoietic cells and implications for gene therapy","volume":"16","author":"M\u00e9tais","year":"2008","journal-title":"Mol. Ther."},{"issue":"24","key":"10.1016\/j.leukres.2023.107349_bib25","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.2010.29.2771","article-title":"Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)\/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia","volume":"28","author":"Lugthart","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2023.107349_bib26","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2023.107349_bib27","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nrc864","article-title":"Live or let die: the cell's response to p53","volume":"2","author":"Vousden","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.leukres.2023.107349_bib28","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/leu.2008.375","article-title":"The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia","volume":"23","author":"Seifert","year":"2009","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2023.107349_bib29","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/1042819031000067620","article-title":"Configuration of the TP53 gene as an independent prognostic parameter of myelodysplastic syndrome","volume":"44","author":"Horiike","year":"2003","journal-title":"Leuk. Lymphoma"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623006148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623006148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:04:00Z","timestamp":1758935040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212623006148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":29,"alternative-id":["S0145212623006148"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107349","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The presence of additional cytogenetic aberrations in chronic myeloid leukemia cells at the time of diagnosis or their appearance on tyrosine kinase inhibitor therapy predicts the imatinib treatment failure","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107349","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107349"}}